AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel International, has completed a Phase I clinical study titled A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. The study aimed to evaluate how food intake affects the pharmacokinetics of the drug combination balcinrenone/dapagliflozin, as well as the pharmacokinetics of balcinrenone when administered with a P-gp inhibitor in healthy individuals.
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how these conditions affect the absorption and action of the drugs.
This was an interventional, randomized, open-label study with a crossover design. Participants were assigned to different sequences of treatments, receiving single doses of the drugs under various conditions. The primary purpose was to assess treatment effects, with no masking involved.
The study began on May 20, 2025, and was completed by August 11, 2025. These dates are crucial for investors as they indicate the timeline for potential data release and subsequent market actions.
The completion of this study could influence AstraZeneca’s stock performance positively, as successful results may lead to further development and eventual market approval of the drug combination. Investors should watch for updates, as these could shift market dynamics, especially in the context of competitors in the cardiovascular treatment space.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.